Joined August 2013
- Tweets 1,633
- Following 241
- Followers 8,987
- Likes 1,485
748 Photos and videos
Pinned Tweet
4 Jan 2021
Editor's Page: The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation. @dranulala @robmentz onlinejcf.com/article/S1071-…
14
38
142
What's new in heart failure research?
Find out in the June edition of JCF, featuring expert perspectives advancing our understanding of heart failure and informing patient care.
Read the full issue: onlinejcf.com/current
2
6
9
894
Time is running out to submit to JCF’s Focus Issue - Artificial Intelligence and Heart Failure: A Critical Juncture.
If your work advances responsible innovation in HF care, now is the time to contribute.⌛
🗓️ Deadline: June 15th, 2026
bit.ly/4kJl5gf
#AIinHealthcare
1
4
13
2,059
In HELIOS-B, vutrisiran slowed renal decline in ATTR-CM: fewer ≥40% eGFR drops vs placebo (12.7% vs 21.2%).
Benefits on CV outcomes were consistent across kidney function, even in advanced CKD.
Improves not just CV outcomes but has renal benefits🫀🧪
bit.ly/3Q2hhf1
12
19
1,966
Cardiac sarcoidosis: beyond steroids?
The REPAIR-CS trial is testing rilonacept (IL-1 blockade) added to standard therapy, with FDG-PET inflammation as the primary endpoint—marking a shift toward targeted, mechanism-based treatment.🫀
🔗 bit.ly/3RijCTs
1
11
21
2,579
When should we biopsy for cardiac sarcoidosis? In ILLUMINATE-CS, EMB positivity (~22%) was directionally associated with established predictors (MIDFIN). Novel predictors: septal thickness, FDG-PET burden, BNP). EMBx yield rose stepwise with number of criteria.
🧵
1
6
13
1,531
But what does a positive biopsy mean?
The editorial notes no association with outcomes, small high-risk subgroups & lack of genetic testing.
EMB may be most valuable earlier, when diagnosis is uncertain and results can change management. 🔍
bit.ly/4dwNrqH
1
4
636
The latest State of the Art Review looks at Immune-mediated pericardial & myocardial syndromes as unified spectrum: linking 🧬 susceptibility, 🌍 triggers & systemic inflammation, with integrated diagnostics & expanding therapies (incl. biologics).
🔗 bit.ly/4dEFcZX
1
13
19
1,194
Acute myocarditis: who is truly at risk?
In a real-world cohort, most patients had favorable outcomes (~88% event-free at 10 yrs).
But higher risk was linked to age, HF symptoms and LV hypokinesia, highlighting the value of early bedside assessment.🫀📊
bit.ly/4dSSd39
1
7
12
730
Do we always need CMR or biopsy in myocarditis?
Accompanying editorial suggests not, questioning their added prognostic value in lower-risk cases & emphasizing simple, accessible tools like echo for risk stratification.
Time to rethink the approach?🔍
bit.ly/4uwn8bt
3
2
234
⬆️ GDF-15 = ⬆️ risk in HFrEF.
In DAPA-HF, dapagliflozin benefit was consistent across GDF-15 levels, but absolute risk reduction was greatest in those with ⏫ levels. Further, dapa did not significantly ⬇️ GDF-15!
GDF-15 is a marker of risk, not response. 🧪🫀
🧵👇
2
4
10
1,154
155
Does sex influence kidney outcomes after heart transplant?
In >30K patients, sex was not associated with early or late kidney failure. Rates of early kidney failure increased after the 2018 allocation change, and this was not impacted by sex. 🫀📊
🔗 bit.ly/4t16mQc
3
6
13
5,555
Severe VHD causes ~4% of cardiogenic shock cases, but with ~40% mortality.
In a multicenter cohort from CCCTN ~1/3 underwent valve intervention, with lower mortality vs conservative care, highlighting a high-risk but potentially treatable subgroup🫀⚠️
🔗 bit.ly/4tJbFoA
1
8
14
2,377
HF with mildly reduced EF (HFmrEF) sits between HFrEF & HFpEF; where does it truly belong?
A new HFSA Scientific Statement examines its epidemiology & pathophysiology & provides a comprehensive management framework for this understudied HF phenotype🫀
🔗 bit.ly/4sKAy21
4
36
63
27,401
Management remains challenging: no trials specifically target HFmrEF.
This HFSA Statement offers a practical framework using available evidence, and highlights key knowledge gaps to guide future research in this growing HF population. 📊
1
1
8
429
Is HFmrEF a distinct entity? 🫀
Evidence suggests it more closely resembles HFrEF—but it may also represent:
• An overlap phenotype
• A transition state (toward HFimpEF or progression from HFpEF)
EF-based categories remain imperfect—but clinically useful. 💡
1
6
301
AI holds untapped potential in heart failure developments, but thoughtful evaluation matters.
JCF’s upcoming Focus Issue will explore where innovation meets evidence, submit your research by June 15th, 2026.
bit.ly/4kJl5gf
#HeartFailure #AIinHealthcare #CallForPapers
1
6
9
1,100
ICYMI: The new scientific statement from @HFSA & @AAHFN!
Integrated health technologies are reshaping HF care, from telemonitoring to mobile apps to implantables.
Benefits include ⬆️QoL & ⬇️hospitalizations, success depends on many complex factors.
🔗 bit.ly/3PyuImr
1
5
10
918
